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ABSTRACT The treatment of infections in critically ill obese and morbidly obese
patients is challenging because of the combined physiological changes that re-
sult from obesity and critical illness. The aim of this study was to describe the
population pharmacokinetics of piperacillin in a cohort of critically ill patients,
including obese and morbidly obese patients. Critically ill patients who received
piperacillin-tazobactam were classiﬁed according to their body mass index (BMI)
as nonobese, obese, and morbidly obese. Plasma samples were collected, and
piperacillin concentrations were determined by a validated chromatographic
method. Population pharmacokinetic analysis and Monte Carlo dosing simulations
were performed using Pmetrics software. Thirty-seven critically ill patients (including
12 obese patients and 12 morbidly obese patients) were enrolled. The patients’
mean  standard deviation age, weight, and BMI were 50  15 years, 104  35 kg,
and 38.0  15.0 kg/m2, respectively. The concentration-time data were best de-
scribed by a two-compartment linear model. The mean  SD parameter estimates
for the ﬁnal covariate model were a clearance of 14.0  7.1 liters/h, a volume of dis-
tribution of the central compartment of 49.0  19.0 liters, an intercompartmental
clearance from the central compartment to the peripheral compartment of 0.9  0.6
liters · h1, and an intercompartmental clearance from the peripheral compartment
to the central compartment of 2.3  2.8 liters · h1. A higher measured creatinine
clearance and shorter-duration infusions were associated with a lower likelihood of
achieving therapeutic piperacillin exposures in patients in all BMI categories. Pipera-
cillin pharmacokinetics are altered in the presence of obesity and critical illness. As
with nonobese patients, prolonged infusions increase the likelihood of achieving
therapeutic concentrations.
KEYWORDS antibiotics, creatinine clearance, dosing, morbid obesity,
pharmacodynamics, pharmacokinetics
In recent decades, obesity has increased in prevalence globally (1, 2). Similar to otherwestern countries, in the United States, more than two-thirds of adults are either
overweight or obese (3, 4). Critically ill obese patients are thought to be at a higher risk
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of mortality and morbidity from serious infections, including surgical site infections and
community-acquired pneumonia, than nonobese patients (5–8). The optimization of
antimicrobial doses should be considered crucial in order to maximize the success of
treatment in these patients, although only sparse data are available to guide dosing (9,
10). Indeed, obesity is thought to augment the pathophysiological changes that occur
due to critical illness, which may lead to additional changes in antimicrobial pharma-
cokinetics (PK) (11, 12). The chronic physiological changes associated with obesity itself
include reduced regional blood ﬂow, increased cardiac output, and increased adipose
tissue mass as well as increased lean mass, all of which may affect antimicrobial
PK/pharmacodynamics (PD) (13).
Piperacillin is a -lactam antibiotic with bactericidal activity against a broad spec-
trum of Gram-negative and Gram-positive aerobes and anaerobes (14). It is commonly
coformulated with tazobactam (a -lactamase inhibitor) to enhance its activity against
-lactamase-producing pathogens (15, 16). Piperacillin exhibits time-dependent bac-
terial killing, meaning that efﬁcacy is determined by the duration that free concentra-
tions are maintained above the MIC (fTMIC) for the pathogens (17). For piperacillin, an
fTMIC of 50% of the dosing interval is considered necessary for maximal activity (18).
There are few data on the PK of piperacillin in obese patients, particularly critically
ill obese patients. Therefore, it remains unclear whether standard piperacillin dosing
regimens will provide sufﬁcient drug exposure. The aim of this prospective study was
to describe the population PK of piperacillin in a cohort of critically ill nonobese, obese,
and morbidly obese patients. We then sought to perform Monte Carlo dosing simula-
tions to identify optimized dosing regimens suitable for critically ill obese and morbidly
obese patients.
RESULTS
Demographic and clinical data. Thirty-seven critically ill patients (21 males) were
enrolled in the study; these included 13 nonobese, 12 obese, and 12 morbidly obese
patients. All patients received dosing every 6 h, except for two patients (body mass
indexes [BMIs], 40.9 and 53.3 kg/m2) that received dosing every 12 h. In total, 222 blood
samples were obtained from the participants. The demographic and clinical character-
istics of the patients with the respective categorizations according to their BMIs are
shown in Table 1. Only the total body weight (TBW), lean body weight (LBW), ideal body
weight (IBW), and BMI were signiﬁcantly different among the patients in the three BMI
categorizations (P  0.05).
TABLE 1 Demographic and clinical dataa
Variable
Values for the following:
P value
All patients
(n  37)
Nonobese patients
(n  13)
Obese patients
(n  12)
Morbidly obese patients
(n  12)
Age (yr) 50 (15) 48 (17) 47 (12) 54 (16) 0.46
Wt (kg) 104 (35) 81 (11) 90 (10) 143 (34) 0.001
IBW (kg) 61 (13) 68 (9) 60 (11) 55 (16) 0.029
LBW (kg) 52 (23) 60 (6) 58 (10) 38 (10) 0.30
Ht (cm) 167 (12) 173 (9) 167 (10) 161 (15) 0.46
Male sexb 21 (57) 11 (84) 6 (50) 4 (33)
BMI (kg/m2) 38 (15) 27 (3) 33 (2) 55 (14) 0.001
Serum creatinine concn (mol/liter) 95 (53) 87 (31) 76 (28) 124 (78) 0.66
Measured CLCR (ml/min) 108 (59) 123 (59) 113 (45) 86 (68) 0.26
CG-TBW (ml/min) 165 (86) 135 (68) 173 (60) 191 (116) 0.25
CG-IBW (ml/min) 103 (58) 117 (66) 114 (40) 77 (58) 0.16
CG-LBW (ml/min) 90 (57) 102 (54) 108 (34) 58 (68) 0.06
SOFA score 6 (3) 7 (3) 7 (4) 4 (4) 0.07
APACHE II score 21 (7) 21 (7) 21 (7) 21 (7) 0.97
aData for each BMI category are presented in a separate column. Data represent means (SDs) unless indicated otherwise. APACHE II, Acute Physiology and Chronic
Health Evaluation II; BMI, body mass index; CG-TBW, CLCR estimated using the Cockcroft-Gault equation based on total body weight; CG-IBW, CLCR estimated using
the Cockcroft-Gault equation based on ideal body weight; CG-LBW, CLCR estimated using the Cockcroft-Gault equation based on lean body weight; CLCR, creatinine
clearance; SOFA, Sequential Organ Failure Assessment.
bData for male sex are presented as the number (percent) of subjects.
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Pharmacokinetic model building. Piperacillin PK were best described using a
two-compartment linear model. The goodness of ﬁt of the model was improved by
inclusion of the following covariates: measured creatinine clearance (CLCR; normalized
to 100 ml/min) for piperacillin clearance and BMI (normalized to 35 kg/m2) for the
piperacillin population volume of distribution of the central compartment (V1). When
these covariates were added, each resulted in a signiﬁcant decrease in the log likeli-
hood. The ﬁnal covariate model was statistically signiﬁcantly better than the structural
model (P  0.05). A scaling factor for obesity (O) was also included for V1 and resulted
in a signiﬁcant improvement to the model (P  0.001). The ﬁnal covariate model was
as follows: TV CL  CL · (CLCR/100) and TV V1  V1 · [(BMI/35)0.75] · O, where TV CL is
the typical value of piperacillin clearance, CL is the population parameter estimate of
piperacillin clearance, CLCR is the measured creatinine clearance, TV V1 is the typical
value of the piperacillin volume of distribution in the central compartment, V1 is the
population parameter estimate of the piperacillin volume of distribution of the central
compartment, BMI is body mass index, and O is a scaling factor for obesity.
The mean standard deviation (SD) population PK parameter estimates for the ﬁnal
covariate model are shown in Table 2. The diagnostic plots conﬁrmed the appropri-
ateness of the model, as shown in Fig. 1a to c. The effect of BMI on piperacillin clearance
and the volume of distribution of the central compartment is shown in Fig. 2 and 3,
respectively. The ﬁnal covariate model was then used for Monte Carlo dosing simula-
tions.
Dosing simulations. Monte Carlo simulations and the probability of target attain-
ment (PTA) of an fTMIC for 50% of the dosing interval for a 4-g piperacillin dose at
various BMIs, for various measured CLCRs, and for different dosing regimens are
presented in Table 3. The results showed that a higher measured CLCR was associated
with a lower PTA in patients in the different BMI classes. At lower and moderate
measured CLCRs (30 and 50 ml/min, respectively), the intermittent dosing regimens of
piperacillin at 4 g every 4 and 6 h showed similar PTAs for nonobese, obese, and
morbidly obese patients. In contrast, piperacillin doses of 4 g every 8 h had variable
PTAs at low to moderate measured CLCRs between the patients in the different BMI
classes. Moreover, the intermittent dosing regimens of piperacillin at 4 g every 4 h for
patients with BMIs of 30 and 40 kg/m2 showed PTAs (MICs  8 mg/liter) higher than
those achieved for patients with a BMI of 20 kg/m2 (MICs  4 mg/liter). All extended
and continuous-infusion dosing regimens of piperacillin achieved the PK/PD targets up
to an MIC of at least 8 mg/liter.
FTA. The fractional target attainment (FTA) for different simulated piperacillin
dosing regimens and patient BMIs and measured CLCRs for both directed and empirical
coverage of infections caused by Acinetobacter baumannii, Escherichia coli, Klebsiella
pneumoniae, and Pseudomonas aeruginosa are shown in Table 4. For A. baumannii
empirical therapy, all piperacillin dosing regimens failed to achieve the 90% target in all
patient groups, including in scenarios with a CLCR of 30 ml/min. Only intermittent
piperacillin dosing every 6 and 8 h failed to achieve the 90% target for A. baumannii-
directed therapy in patients with BMIs of 20 and 30 kg/m2 at a higher CLCR (150
TABLE 2 Parameter estimates for piperacillin from the ﬁnal two-compartment covariate
population PK model
Parametera Mean (SD) Coefﬁcient of variation (%) Median
CL (liters/h) 14.0 (7.1) 51.38 10.72
V1 (liters) 49.0 (19.0) 37.68 57.97
kcp (h1) 0.9 (0. 6) 68.02 0.80
kpc (h1) 2.3 (2.8) 120.360 1.36
O 0.4 (0.2) 43.87 0.27
aCL, population clearance of piperacillin; V1, population volume of distribution of central compartment; kcp,
rate constant for the piperacillin distribution from the central to the peripheral compartment; kpc, rate
constant for the piperacillin distribution from the peripheral to the central compartment; O, scaling factor
for obesity.
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ml/min). Prolonged piperacillin infusions as directed therapy achieved the 90% target
for E. coli, K. pneumoniae, and P. aeruginosa in all groups of patients. Moreover, almost
all piperacillin dosing regimens failed to achieve the 90% target for P. aeruginosa in all
groups of patients, particularly in patients with CLCRs of 50 ml/min.
DISCUSSION
Key ﬁndings. This is the ﬁrst study of the population PK of piperacillin targeted at
critically ill nonobese, obese, and morbidly obese patients. We found that both BMI and
FIG 1 Diagnostic plots for the ﬁnal population pharmacokinetic covariate model. (a) Observed piperacillin concentrations versus population predicted
concentration (R2  0.653); (b) observed piperacillin concentrations versus individual predicted concentrations (R2  0.976); (c) visual predictive check. The
median and 5th and 95th percentiles of simulated data with their respective 95% conﬁdence intervals (CI; light gray ﬁelds) are shown. Individual points
represent observed data. Inter, intercept.
FIG 2 Effect of BMI class on piperacillin clearance.
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CLCR signiﬁcantly affected piperacillin PK. Furthermore, as expected, we found that
more frequent intermittent piperacillin doses produced a higher PTA across all BMI
categories. We also found that piperacillin extended and continuous infusions greatly
improved the PTA (an MIC up to at least 8 mg/liter) in the presence of different BMIs
and measured CLCRs. These data support those of other investigators (19–21), which
suggest that extended and continuous infusions can normalize any effects of altered
weight and renal function on achievement of therapeutic concentrations.
Relationship with previous papers. The PK of piperacillin in critically ill nonobese
patients appear to be different from those in healthy subjects (22). This is likely due to
the pathophysiological alterations that occur in critically ill patients, such as organ
dysfunction, including renal and hepatic dysfunction, as well as ﬂuid shifts and capillary
permeability changes that can alter the piperacillin clearance and volume of distribu-
tion (12, 23). The presence of obesity may exaggerate these effects. However, to date,
there is a shortage of studies on the PK of piperacillin in obese critically ill patients. Hites
et al. (24) found that neither the piperacillin volume of distribution nor the piperacillin
clearance was signiﬁcantly different between obese and nonobese critically ill patients.
However, the authors suggested that therapeutic drug monitoring (TDM) still be used
for critically ill patients, including obese patients, as critically illness itself is responsible
for largely unpredictable PK alterations.
In contrast, Sturm et al. (25) examined piperacillin PK in 9 morbidly obese critically
ill patients and found that the volume of distribution of piperacillin in morbidly obese
critically ill patients was higher than that in nonobese patients (31.0 liters versus 22.4
liters, respectively) and that the clearance of piperacillin was lower in morbidly obese
critically ill patients than nonobese patients (6.0 liters/h versus 13.7 liters/h, respec-
tively). At a piperacillin dose of 4 g administered over 30 min every 6 h, all patients in
the study achieved the PK/PD target of an fTMIC for 50% of the dosing interval when a
higher MIC target (16 mg/liter) was used. The authors suggested that piperacillin
administered as a 4-h extended infusion appears to have little advantage over pipera-
cillin administered as a shorter 30-min infusion. This conclusion conﬂicts with our
ﬁndings that showed that piperacillin extended and continuous infusions increased the
rate of PK/PD target achievement compared to that achieved with intermittent regi-
mens, particularly in patients with higher CLCRs.
A large retrospective study of 1,400 patients by Alobaid et al. (26) examined the
impact of obesity on the unbound plasma concentrations of piperacillin and mero-
penem. That study showed that obesity was associated with signiﬁcantly lower un-
bound piperacillin concentrations in obese patients (29.4 mg/liter) than nonobese
patients (42.0 mg/liter). Similarly, in the present study, we found that piperacillin
clearance was higher in the morbidly obese group (19.7  8.6 liters/h) than both the
obese group (11.1 3.0 liters/h) and the nonobese group (10.7 5.0 liters/h), as shown
FIG 3 Effect of BMI class on the piperacillin volume of distribution of the central compartment.
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TABLE 3 PTA of piperacillin at 4 g for various BMIs, measured CLCRs, dosing intervals, and durations of infusiona
Frequency and type
of dosing
BMI
(kg/m2)
CLCR
(ml/min)
Achievement of PTA for MIC of:
0.25
mg/liter
0.50
mg/liter
1
mg/liter
2
mg/liter
4
mg/liter
8
mg/liter
16
mg/liter
32
mg/liter
64
mg/liter
Dosing every 4 h
Intermittent 20 30         
20 50         
20 150         
30 30         
30 50         
30 150         
40 30         
40 50         
40 150         
Extended infusion 20 30         
20 50         
20 150         
30 30         
30 50         
30 150         
40 30         
40 50         
40 150         
Continuous infusion 20 30         
20 50         
20 150         
30 30         
30 50         
30 150         
40 30         
40 50         
40 150         
Dosing every 6 h
Intermittent 20 30         
20 50         
20 150         
30 30         
30 50         
30 150         
40 30         
40 50         
40 150         
Extended infusion 20 30         
20 50         
20 150         
30 30         
30 50         
30 150         
40 30         
40 50         
40 150         
Continuous infusion 20 30         
20 50         
20 150         
30 30         
30 50         
30 150         
40 30         
40 50         
40 150         
Dosing every 8 h
Intermittent 20 30         
20 50         
20 150         
30 30         
(Continued on following page)
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in Fig. 2. We also found that an increase in the BMI was signiﬁcantly associated with an
increase in V1, highlighting the effect of an increase in obesity on likely changes in
piperacillin exposure. This result is likely due to the consequent prolongation of the
drug half-life associated with an increase in V1, leading to more sustained periods when
the concentrations exceed the therapeutic concentration target.
A study by Roberts et al. (22) investigated the PK of piperacillin administered by
either continuous or intermittent dosing in critically ill patients with sepsis, including
obese patients. The authors found that both the piperacillin volume of distribution and
the piperacillin clearance were higher in critically ill patients with sepsis than healthy
adults (25.0 liters versus 10.4 liters for the volume of distribution and 17.2 liters/h versus
11.3 liters/h for clearance) (27). The authors used a simulation approach to show that
an increased length of infusion could increase the rate of achievement of therapeutic
concentrations in the presence of the pathophysiological changes associated with
critical illness. Furthermore, Cheatham et al. (28) found that the piperacillin volume of
distribution and clearance were numerically higher in obese non-critically ill patients
than in nonobese non-critically ill patients (33.4 liters versus 21.8 liters for volume of
distribution and 13.7 liters/h versus 8.6 liters/h for clearance). The authors suggested
that a higher piperacillin dose was necessary to ensure achievement of therapeutic
concentrations.
Implications of study ﬁndings. Our results suggest that different piperacillin
dosing regimens should be used to increase the rate of PK/PD target attainment in
critically ill patients on the basis of their renal function and BMI. A 4-g piperacillin
intermittent dose (administered every 6 and 8 h) for obese/nonobese critically ill
patients with low to moderate measured CLCRs appears to be appropriate for targeting
pathogens with MICs of 8 mg/liter, such as E. coli. However, in patients with higher
measured CLCRs or when pathogens with higher MICs (16 mg/liter), such as P.
aeruginosa, are suspected, the piperacillin dose is best given more frequently (every 4
h) to achieve PK/PD targets.
TABLE 3 (Continued)
Frequency and type
of dosing
BMI
(kg/m2)
CLCR
(ml/min)
Achievement of PTA for MIC of:
0.25
mg/liter
0.50
mg/liter
1
mg/liter
2
mg/liter
4
mg/liter
8
mg/liter
16
mg/liter
32
mg/liter
64
mg/liter
30 50         
30 150         
40 30         
40 50         
40 150         
Extended infusion 20 30         
20 50         
20 150         
30 30         
30 50         
30 150         
40 30         
40 50         
40 150         
Continuous infusion 20 30         
20 50         
20 150         
30 30         
30 50         
30 150         
40 30         
40 50         
40 150         
aThe probability of target attainment was the probability that the free drug concentrations remains above the MIC for 50% of the dosing interval to achieve
bactericidal activity. , the probability of target attainment for piperacillin of at least 90% was achieved; , the probability of target attainment for piperacillin failed
to achieve a value of 90%; BMI, body mass index; CLCR, measured creatinine clearance.
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TABLE 4 FTA with piperacillin at 4 g for various BMIs, measured CLCRs, dosing intervals, and methods of administrations for Acinetobacter
baumannii, Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosaa
Frequency and type of
dosing
BMI
(kg/m2)
CLCR
(ml/min)
% patients infected with the following pathogen achieving the indicated MIC:
A. baumannii E. coli K. pneumoniae P. aeruginosa
MIC for
directed
therapy
MIC for
empirical
therapy
MIC for
directed
therapy
MIC for
empirical
therapy
MIC for
directed
therapy
MIC for
empirical
therapy
MIC for
directed
therapy
MIC for
empirical
therapy
Dosing every 4 h
Intermittent h 20 30 100.00 68.76 100.00 98.94 100.00 95.26 99.99 93.08
20 50 99.96 55.60 99.98 98.02 99.96 92.04 99.92 87.18
20 150 94.14 32.97 97.33 92.25 95.41 81.75 84.95 66.11
30 30 100.00 67.86 100.00 98.91 100.00 95.09 100.00 92.82
30 50 99.98 55.97 100.00 98.08 99.99 92.12 99.96 87.40
30 150 97.41 35.45 98.92 94.16 98.06 84.75 91.33 71.35
40 30 100.00 70.50 100.00 98.84 100.00 94.81 100.00 92.35
40 50 100.00 55.84 100.00 98.08 100.00 92.07 99.99 87.35
40 150 100.00 41.48 99.58 95.05 99.11 86.16 94.22 73.75
Extended infusion h 20 30 100.00 69.89 100.00 99.02 100.00 95.56 100.00 93.63
20 50 100.00 57.80 100.00 98.24 100.00 92.55 100.00 88.32
20 150 100.00 41.46 100.00 96.47 100.00 88.78 99.94 79.73
30 30 100.00 67.72 100.00 98.90 100.00 95.05 100.00 92.76
30 50 100.00 57.02 100.00 98.18 100.00 92.36 100.00 87.94
30 150 100.00 40.25 100.00 96.27 100.00 88.45 99.78 78.90
40 30 100.00 67.06 100.00 98.87 100.00 94.93 100.00 92.57
40 50 100.00 56.53 100.00 98.14 100.00 92.24 100.00 87.70
40 150 100.00 40.82 100.00 96.37 100.00 88.62 99.88 79.31
Continuous infusion 20 30 100.00 73.07 100.00 99.17 100.00 96.22 100.00 94.70
20 50 100.00 59.57 100.00 98.36 100.00 92.96 100.00 89.09
20 150 100.00 41.53 100.00 96.47 100.00 88.77 99.84 79.70
30 30 100.00 71.72 100.00 99.12 100.00 96.00 100.00 94.34
30 50 100.00 59.14 100.00 98.33 100.00 92.84 100.00 88.89
30 150 100.00 41.51 100.00 96.46 100.00 88.76 99.84 79.68
40 30 100.00 70.50 100.00 99.06 100.00 95.74 100.00 93.90
40 50 100.00 58.63 100.00 98.30 100.00 92.70 100.00 88.65
40 150 100.00 41.48 100.00 96.46 100.00 88.76 99.84 79.67
Dosing every 6 h
Intermittent 20 30 99.98 57.38 100.00 98.18 99.99 92.48 99.95 88.07
20 50 99.78 46.83 99.81 96.92 99.73 89.70 99.15 82.22
20 150 79.81 25.04 84.98 79.73 78.24 65.64 58.69 45.08
30 30 100.00 57.01 100.00 98.17 100.00 92.37 100.00 87.92
30 50 99.93 47.85 99.97 97.25 99.93 90.15 99.69 83.13
30 150 86.99 28.15 92.93 87.45 88.61 74.81 72.14 55.51
40 30 100.00 56.33 100.00 98.11 100.00 92.18 100.00 87.58
40 50 99.95 47.93 99.99 97.31 99.98 90.23 99.86 83.31
40 150 91.32 29.91 96.11 90.57 93.15 78.85 78.96 60.80
Extended infusion 20 30 100.00 58.67 100.00 98.30 100.00 92.75 100.00 88.71
20 50 100.00 58.67 100.00 98.23 100.00 92.75 100.00 88.71
20 150 99.98 36.64 100.00 98.14 99.99 87.06 97.37 75.50
30 30 100.00 57.72 100.00 98.30 100.00 92.52 100.00 88.25
30 50 100.00 49.56 100.00 97.53 100.00 90.65 100.00 84.29
30 150 99.98 36.33 100.00 97.47 99.99 86.91 97.01 75.13
40 30 100.00 56.51 100.00 95.50 100.00 92.20 100.00 87.66
40 50 100.00 49.00 100.00 95.42 100.00 90.52 100.00 84.01
40 150 99.98 36.17 100.00 95.37 99.99 86.81 96.72 74.89
Continuous infusion 20 30 100.00 61.85 100.00 98.53 100.00 93.58 100.00 90.21
20 50 100.00 51.71 100.00 97.72 100.00 91.15 100.00 85.36
20 150 100.00 36.24 100.00 95.38 100.00 86.83 96.70 74.93
30 30 100.00 60.93 100.00 98.47 100.00 93.34 100.00 89.79
30 50 100.00 51.47 100.00 97.70 100.00 91.08 100.00 85.24
30 150 100.00 36.24 100.00 95.38 100.00 86.83 96.72 74.93
40 30 100.00 59.92 100.00 98.40 100.00 93.07 100.00 89.30
40 50 100.00 51.14 100.00 97.68 100.00 90.99 100.00 85.07
40 150 100.00 36.24 100.00 95.38 100.00 86.83 96.70 74.93
(Continued on following page)
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Furthermore, less frequent prolonged piperacillin infusions could also be considered
when targeting pathogens with MICs of 8 mg/liter in obese/nonobese critically ill
patients, including those patients with a higher measured CLCR. Prolonged piperacillin
infusion (e.g., 4 g every 6 h as a 3-h infusion) is recommended for the targeting of
pathogens with MICs of 16 mg/liter for patients with a higher measured CLCR (150
ml/min). However, knowledge of patient renal function is important and should be
used for more accurate dose individualization.
When piperacillin is considered for empirical therapy, all dosing regimens failed to
achieve the 90% target for both A. baumannii and P. aeruginosa. In such cases it would
appear that combination therapy would be appropriate to ensure maximal therapy.
Study limitations. Although this study is the ﬁrst study of the population PK of
piperacillin in critically ill nonobese, obese, and morbidly obese patients, it has some
limitations that should be declared. First, even though the drug formulation contained
both piperacillin (a -lactam antibiotic) and tazobactam (a -lactamase inhibitor), we
did not measure tazobactam concentrations. Second, even though this is considered a
relatively large PK study in critically ill patients, the sample size would not be consid-
ered sufﬁcient for quantifying the effect of piperacillin exposure on patient outcome.
Finally, we collected only blood samples, which may not necessarily indicate the
concentrations at the site of infection, and more speciﬁc mechanistic studies would be
required to determine penetration into the interstitial ﬂuid of different tissues of obese
and morbidly obese patients.
Conclusion. In summary, this study presents the ﬁrst population PK study of
piperacillin in critically ill patients in three different BMI categories. Although an
increase in the BMI does not appear to have a large effect on the probability of PK/PD
TABLE 4 (Continued)
Frequency and type of
dosing
BMI
(kg/m2)
CLCR
(ml/min)
% patients infected with the following pathogen achieving the indicated MIC:
A. baumannii E. coli K. pneumoniae P. aeruginosa
MIC for
directed
therapy
MIC for
empirical
therapy
MIC for
directed
therapy
MIC for
empirical
therapy
MIC for
directed
therapy
MIC for
empirical
therapy
MIC for
directed
therapy
MIC for
empirical
therapy
Dosing every 8 h
Intermittent 20 30 99.89 49.53 99.97 97.40 99.93 90.54 99.62 83.93
20 50 97.68 38.64 98.67 94.59 97.98 85.88 93.74 74.45
20 150 56.54 16.86 49.48 46.23 40.36 33.54 24.71 18.86
30 30 100.00 50.09 100.00 97.52 100.00 90.74 99.93 84.43
30 50 99.15 40.78 99.63 95.88 99.35 87.74 97.16 77.74
30 150 66.85 20.14 67.31 62.94 57.52 47.91 37.78 28.85
40 30 100.00 50.01 100.00 97.54 100.00 90.72 99.97 84.44
40 50 99.65 41.82 99.91 96.34 99.78 88.45 98.39 79.05
40 150 73.43 22.36 78.50 73.47 69.42 57.94 47.90 36.60
Extended infusion 20 30 100.00 53.51 100.00 97.89 100.00 91.52 100.00 86.23
20 50 100.00 45.99 100.00 97.12 100.00 89.85 100.00 82.39
20 150 99.18 32.95 200.64 94.36 99.69 84.85 91.34 70.16
30 30 100.00 52.23 100.00 97.77 100.00 91.21 100.00 85.59
30 50 100.00 45.55 100.00 97.06 100.00 89.75 100.00 82.15
30 150 99.25 33.08 99.88 94.41 99.72 84.94 91.62 70.38
40 30 100.00 51.31 100.00 97.69 100.00 91.01 100.00 85.14
40 50 100.00 45.07 100.00 97.00 100.00 89.64 99.99 81.88
40 150 99.33 33.10 99.89 94.42 99.74 84.97 91.72 70.45
Continuous infusion 20 30 100.00 55.84 100.00 98.07 100.00 92.11 100.00 87.38
20 50 100.00 47.21 100.00 97.25 100.00 90.14 100.00 83.04
20 150 99.73 33.32 99.96 94.52 99.90 85.18 92.34 70.92
30 30 100.00 55.39 100.00 98.04 100.00 91.99 100.00 87.15
30 50 100.00 47.15 100.00 97.25 100.00 90.12 100.00 83.01
30 150 99.73 33.32 99.96 94.52 99.90 85.18 92.34 70.92
40 30 100.00 54.73 100.00 97.99 100.00 91.81 100.00 86.82
40 50 100.00 47.05 100.00 97.24 100.00 90.09 100.00 82.96
40 150 99.73 33.31 99.96 94.52 99.90 85.17 92.32 70.91
aShading indicates piperacillin FTA attainment failed to achieve 90%. BMI, body mass index; CLCR, creatinine clearance.
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target attainment in critically ill patients, an increase in the measured CLCR was strongly
associated with a lower probability of PK/PD target attainment. A piperacillin dose of 4
g every 4, 6, or 8 h as a prolonged infusion is required to achieve the PK/PD targets.
Also, the use of more frequent intermittent or higher intermittent doses provides
another option for less susceptible pathogens, including P. aeruginosa, and/or in
critically ill obese and nonobese patients with high CLCRs. TDM of piperacillin should be
used where available for dose optimization.
MATERIALS AND METHODS
Setting. This was an observational PK study at a tertiary referral intensive care unit (ICU). Ethical
approval was obtained from the Queensland Royal Brisbane and Women’s Hospital Human Research
Ethics Committee (HREC/14/QRBW/88). Written informed consent was obtained from all participants or
from their substitute decision makers.
Study population. The inclusion criteria for this study were (i) an age of 18 years, (ii) treatment
with piperacillin, and (iii) a BMI of 18.5 kg/m2. The exclusion criteria were (i) renal replacement therapy
(RRT), (ii) pregnancy for women, (iii) active bleeding, and (iv) HIV infection or hepatitis.
Study protocol. Piperacillin was administered at the discretion of the treating clinician at dosage
regimens of 4 g every 6 or 12 h as a 20-min infusion. Participants were categorized into one of three
groups according to their BMI, as follows: normal weight (BMI  18.5 to 29.9 kg/m2), obese (BMI  30
to 39.9 kg/m2), and morbidly obese (BMI  40 kg/m2). During one dosing interval, blood samples (3
ml) were taken from each participant to determine total plasma piperacillin concentrations at the
following times: before administration of the dose and at 20 min (the end of infusion), 40 min, and 1, 3.5,
and 6 h after administration of the dose. Clinical and demographic data were collected on the day of
sampling, including age, sex, total body weight (TBW), ideal body weight (IBW), lean body weight (LBW),
and BMI, (29). Clinical data were also recorded, including Sequential Organ Failure Assessment (SOFA)
(30) and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores (31), as well as the serum
albumin and serum creatinine concentrations and the CLCR estimated by the Cockcroft-Gault equation
(32) separately using TBW, LBW, and IBW. Urine samples were also collected over the dosing interval to
determine the measured CLCR.
Sample handling, storage, and assay. Blood samples were placed in an ice bath immediately upon
collection and centrifuged at 3,000 rpm for 10 min. Plasma samples were stored at 80°C until
bioanalysis. The piperacillin concentration (0.5 to 500 mg/liter) in plasma was measured by a validated
ultra-high-performance liquid chromatography (UHPLC)-tandem mass spectrometry (MS/MS) method on
a Shimadzu Nexera2 UHPLC system coupled to a Shimadzu 8030 triple quadruple mass spectrometer
(Shimadzu, Kyoto, Japan). Clinical samples were assayed alongside plasma calibrators and quality
controls and met batch acceptance criteria (33).
Plasma (2.5 l) was spiked with the internal standard ([d5]-piperacillin), treated with acetonitrile, and
centrifuged. The supernatant (0.5 l) was injected into the UHPLC-MS/MS. The stationary phase was a C18
Shimadzu Shim-pack XR-ODS III 1.6-m column (Shimadzu, Kyoto, Japan) operated at room tempera-
ture. Mobile phase A was 0.1% (vol/vol) formic acid in water, and mobile phase B was 100%
acetonitrile with 0.1% (vol/vol) formic acid. The gradient went from 7.5% mobile phase B to 95%
mobile phase B and back again for an 8.0-min run time. The ﬂow rate was 0.3 ml/min and produced
a backpressure of about 5,000 lb/in2. Piperacillin was monitored by positive mode electrospray at a
multiple reaction monitoring level of 518.00 ¡ 143.00. [d5]-piperacillin was monitored in the
positive mode at 523.00 ¡ 148.00.
The assay method was validated for linearity, matrix test, selectivity, lower limit of quantitation,
recovery, reinjection stability, precision, and accuracy using the FDA criteria for bioanalysis (33). Precision
was within 5.8% and accuracy was within 10.0% at the tested plasma quality control piperacillin
concentrations of 1.5, 50, and 400 mg/liter.
Population pharmacokinetic modeling. One- and two-compartment models were developed
using the nonparametric adaptive grid algorithm within the Pmetrics package for R (Los Angeles, CA,
USA) (34, 35).
We tested demographic and clinical characteristics for inclusion as covariates if they were biologically
plausible for affecting piperacillin PK. The covariates assessed included age, sex, TBW, IBW, LBW, BMI,
serum creatinine concentration, measured CLCR, CLCR estimated by the Cockcroft-Gault equation (sepa-
rately using TBW, LBW and IBW), albumin concentration, SOFA score, and APACHE II score. Covariates
that signiﬁcantly reduced the log likelihood (P  0.05) and/or improved the goodness-of-ﬁt plots were
included in the model.
Model diagnostics. The goodness of ﬁt of each model was evaluated by visual inspection of the
observed-predicted (population and individual) concentration scatter plots. The coefﬁcient of determi-
nation of the linear regression of the observed-predicted values and the log likelihood values from each
run were also used to assess the goodness of ﬁt. The predictive performance was evaluated using the
mean prediction error (bias) and mean bias-adjusted squared prediction error (imprecision) for the
population and individual predicted concentrations in the central compartment. The suitability of
the ﬁnal covariate model was assessed using a visual predictive check (VPC) after bootstrap resampling
method (n  1,000 simulations) and normalized prediction distribution errors (36).
PTA. Monte Carlo simulations (n  1,000) were performed using Pmetrics software to determine the
probability of target attainment (PTA) of an fTMIC of 50% of the dosing interval (18) for a variety of MICs
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and for measured CLCR and BMI classes. Piperacillin doses of 4 g intravenously every 4, 6, and 8 h as a
30-min intermittent infusion, a 2-h (dosing every 4 h), 3-h (dosing every 6 h), or 4-h (dosing every 8 h)
extended infusion, or a continuous infusion (after administration of a 4-g loading dose over 30 min) were
simulated at three different levels of renal function (measured CLCRs 30, 50 and 150 ml/min) and three
BMI classes of 20, 30, and 40 kg/m2.
Calculation of FTA.MIC data for Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, and
Pseudomonas aeruginosa were used to determine the fractional target attainment (FTA) according to the
MIC distributions from the European Committee for Antimicrobial Susceptibility and Testing (EUCAST)
database (37). The FTA compares the PK/PD exposure (PTA) against an MIC distribution to identify the
rate of achievement of the target piperacillin exposure against the distribution of susceptibilities of the
pathogen. A piperacillin dosing regimen was considered successful if the FTA value was 90%. MIC
distributions for susceptibility for these pathogens (an MIC of 8 mg/liter for A. baumannii, E. coli, and
K. pneumoniae and an MIC of 16 mg/liter P. aeruginosa) were used to determine the FTA for directed
therapy. Additionally, we used the entire MIC distribution (MICs for the susceptibility and resistance of
the isolates) to determine the FTA, as would be encountered with empirical monotherapy.
Statistical analysis. Demographic data were analyzed using the statistical software package IBM-
SPSS statistics (version 22.0; IBM, New York, NY, USA). Continuous variables were deﬁned as the mean
(standard deviation [SD]). A P value of 0.05 was considered statistically signiﬁcant.
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